Paclitaxel induces apoptosis in AIDS-related Kaposi's sarcoma cells

Sarcoma

Volumn 4, Issue 1-2, 2000, Pages 37-45

  Cai, Jie ^a   Zheng, Tong ^a   Masood, Rizwan ^a   Smith, D Lynne ^a   Hinton, David R ^a   Kim, Caryn Nae ^b   Fang, Guofu ^b   Bhalla, Kapil ^b   Gill, Parkash S ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Kenneth Norris Jr Cancer H ^*

Author keywords

AIDS; Apoptosis; Kaposi's sarcoma; Paclitaxel; Taxol

Indexed keywords

CYTOCHROME C OXIDASE; ETOPOSIDE; PACLITAXEL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL MIGRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPOSI SARCOMA; LABELING INDEX; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0033927620     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1155/s1357714x00000074     Document Type: Article

References (43)

1. 1 Gill PS, Hamilton AW, Naidu Y. Epidemic (AIDS-related) Kaposi's sarcoma: epidemiology, pathogenesis, and treatment. AIDS Updates 1994;7:1-11.
2. 2 Rabkin CS, Janz S, Lash A, Coleman AE, Musaba E, Liotta L, et al. Monocolonal origin of multicentric Kaposi's sarcoma Lesions. N Engl J Med 1997;336:988-93.
3. 3 Gill PS, Tsai YC, Rao AP, Spnick CH 3rd, Zheng T, Harrington WA Jr., et al. Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad of Sci USA 1998;95:8257-61.
4. 4 Albini A, Aluigi MG, Benelli R, Berti E, Biberfeld P, Blasig G, et al. Oncogenesis in HIV-infection: KSHV and Kaposi's sarcoma. Int J Oncol 1996;9:5-8.
5. 5 Chatlynne LG, Ablashi DV. Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV). Semin Cancer Biol 1999;9:175-85.
6. 6 Lunardi-Iskandar Y, Gill PS, Lam VH, Zeman RA, Michaels F, Mann DL, et al. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma. J Natl Can Inst 1995;87:974-81.
7. 7 Fiorelli V, Gendelman R, Sirianni MC, Chang HK, Colombini S, Markham PD, et al. γ-interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with HFV-1 Tat protein: an immune response to HHV-8 infection? Blood 1998;91:956-67.
8. 8 Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B. Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells. J Clin Invest 1995;95:1723-34.
9. 9 Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular Endothelial Growth Factor/Vascular permeability factor (VEGF/VPF) in as autocrine growth factor for AIDS-KS. Proc Natl Acad Sci USA 1997;94:979-84.
10. 10 Weninger W, Partanen TA, Breiteneder-Geleff S, Mayer C, Kowalski H, Mildner M, Pammer, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999;79:243-51.
11. 11 McGarvey ME, Flore O, Masood R, Arora N, Zheng T, Smith DL, et al. Expression of endothelial cell specific receptor tyrosine kinases, Tie-1 and Tie-2, Flt-1, Flk-1 and Flt-4 in Kaposi's sarcoma cell lines and in primary tumor tissues. Blood 1998;92:538.
12. 12 Ensoli B, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, et al. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor: a novel strategy for the therapy of KS. J Clin Invest 1994;94:1736-46.
13. 13 Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
14. 14 McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
15. 15 Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 1991;83:1779-1805.
16. 16 Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, et al. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 1995;346:26-8.
17. 17 Horwitz SB, Cohen D, Rao S, Ringel I, Shen H-J, Yang C-PH. Taxol: mechanisms of action and resitance. Monographs, J Natl Cancer Inst 1993;15:55-62.
18. 18 Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and taxol induced growth arrest. J Biol Chem 1998;273:30 777-84.
19. 19 Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7:541-6.
20. 20 Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Medicine 1997;3:614-20.
21. 21 Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
22. 22 Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3878-85.
23. 23 Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-32.
24. 24 Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 1998;95:4997-5002.
25. 25 Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
26. 26 Harvey KJ, Blomquist JF, Ucker DS. Commitment and effector phases of the physiological cell death pathway elucidated with respect to Bcl-2 caspase, and cyclin-dependent kinase activities. Mol Cell Biol 1998;18:2912-22.
27. 27 Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
28. 28 Burt HM, Jackson JK, Bains SK, Liggins RT, Oktaba AM, Arsenault AL, et al. Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid). Cancer Lett 1995;88:73-9.
29. 29 Klauber N, Parangi S, Flynn E, Hamel E, Damato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
30. 30 Lunardi-Iskandar Y, Gill P, Lam VH, Zeman RA, Michaels F, Mann DL, et al. Isolation and characterization of an immortal neoplastic cell line (KS Y1) from AIDS-associated Kaposi's sarcoma. J Natl Cancer Inst 1995;87:974-81.
31. 31 Siegal B, Levinton-Kriss S, Schiffer A, Sayar J, Engelberg I, Vonsover A, et al. Kaposi's sarcoma in immunosuppression. Possibly the results of dual viral infection. Cancer 1990;65:492-8.
32. 32 Ray S, Ponnathpur V, Huang Y, Tang C, Mahoney ME, Ibrado AM, et al. 1-β-D-arabinofuranosylcytosine-, mitoxantrone- and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol 1994;34:365-71.
33. 33 Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassotta P, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992;13:795-808.
34. 34 Bhalla K, Ibrado AM, Tourkina E, Tang CQ, Mahoney ME, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemic cell. Leukemia 1993;7:563-8.
35. l. overexpression inhibits Taxol-induced Yama protease activity and apoptosis. Cell Growth and Differentiation 1996;7:1087-94.
36. 36 Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
37. 37 Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell 1995;82:349-52.
38. l. overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human AML HL-60 cells. Cancer Res 1997;47:1109-15.
39. 39 Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, et al. Paclitaxel is safe and effective in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 1999;17:1876-83.
40. 40 Tortora G, di Isernia G, Sandomenico C, Bianco R, Pomatico G, Pepe S, et al. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells Cancer Res 1997;57:5107-11.
41. 2M cell cycle arrest. Br J Cancer 1998;77:404-11.
42. 42 Gagandeep S, Novikoff PM, Ott M, Gupta S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett 1999;136:109-18.
43. 43 Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999;162:6811-8.